Logo.png
Rich Insights Into The Robust Metastatic Melanoma Clinical Trials Pipeline Analysis Featuring 75+ Companies DelveInsight
August 18, 2022 13:00 ET | DelveInsight Business Research LLP
New York, USA, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Rich Insights Into The Robust Metastatic Melanoma Clinical Trials Pipeline Analysis Featuring 75+ Companies DelveInsight The prevalence of skin...
Attachment.jpg
Mountain Valley MD Holdings Provides Business Update, Results of Shareholder Meeting
September 29, 2021 16:01 ET | Mountain Valley MD Holdings Inc.
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to provide a business update on key...
provectus_logo.jpg
Provectus Announces Presentation of Updated Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Naïve Advanced Melanoma at SMR 2019 Congress
November 21, 2019 09:00 ET | Provectus Biopharmaceuticals Inc.
Full accrual of 21 checkpoint-naïve melanoma patientsNo safety concerns identified; no significant overlap of toxicities95% 12-month OS rate; 100% 12-month DSS rate; Median PFS of 11.7 months10% CR...